| 陈艳茹,刘 暘,石鑫岳,张晓炜,李 瑞.昆仙胶囊联合甲氨蝶呤对类风湿关节炎患者疾病活动因子、骨代谢指标和Th17细胞的影响[J].,2024,(21):4170-4172 |
| 昆仙胶囊联合甲氨蝶呤对类风湿关节炎患者疾病活动因子、骨代谢指标和Th17细胞的影响 |
| Effects of Kunxian Capsules Combined with Methotrexate on Disease Activity Factors, Bone Metabolism Indexes and Th17 Cells in Rheumatoid Arthritis Patients |
| 投稿时间：2024-05-24 修订日期：2024-06-20 |
| DOI：10.13241/j.cnki.pmb.2024.21.035 |
| 中文关键词: 昆仙胶囊 甲氨蝶呤 类风湿关节炎 疾病活动因子 骨代谢指标 Th17细胞 |
| 英文关键词: Kunxian capsules Methotrexate Rheumatoid arthritis Disease activity factors Bone metabolism indexes Th17 cells |
| 基金项目:中央引导地方科技发展资金项目（2022ZY0184） |
|
| 摘要点击次数: 41 |
| 全文下载次数: 19 |
| 中文摘要: |
| 摘要 目的：观察昆仙胶囊联合甲氨蝶呤对类风湿关节炎（RA）患者疾病活动因子、骨代谢指标和辅助T（Th）17细胞的影响。方法：152例RA患者采用随机数字表法分为对照组（甲氨蝶呤治疗，76例）、研究组（昆仙胶囊联合甲氨蝶呤治疗，76例）。对比两组临床疗效、疾病活动因子[C反应蛋白（CRP）、类风湿因子（RF）、血沉（ESR）]、骨代谢指标[骨保护素（OPG）、 核因子κB受体活化剂配体（RANKL）]和Th17细胞[外周血Th17细胞比例、白细胞介素（IL）-22、IL-17]，同时观察两组治疗安全性。结果：与对照组治疗后相比，研究组临床总有效率更高，CRP、RF、ESR、RANKL、Th17细胞比例、IL-17、IL-22下降幅度更大，OPG升高幅度更大（P<0.05）。两组不良反应发生率对比无差异（P>0.05）。结论：昆仙胶囊联合甲氨蝶呤治疗RA患者，可通过控制疾病活动因子、调节骨代谢指标和Th17细胞来提升治疗效果，且具有较好的安全性。 |
| 英文摘要: |
| ABSTRACT Objective: To observe the effects of kunxian capsules combined with methotrexate on disease activity factors, bone metabolism indexes and helper T (Th) 17 cells in rheumatoid arthritis (RA) patients. Methods: From 152 RA patients were divided into control group (methotrexate treatment, 76 cases) and study group (Kunxian capsule combined with methotrexate treatment, 76 cases) by random number table method. The clinical efficacy, disease activity factors [C-reactive protein (CRP), rheumatoid factor (RF), erythrocyte sedimentation rate (ESR)], bone metabolism indexes [osteoprotegerin (OPG), receptor activator of nuclear factor-κB ligand (RANKL)] and Th17 cells [peripheral blood Th17 cell ratio, interleukin (IL)-22, IL-17] were compared between two groups, and the safety in two groups was observed. Results: Compared with control group after treatment, the total effective rate in study group was higher, CRP, RF, ESR, RANKL, Th17 cell ratio, IL-17, IL-22 decreased more, OPG increased more(P<0.05). There was no difference in the incidence of adverse reactions between two groups(P>0.05). Conclusion: Kunxian capsules combined with methotrexate in the treatment of RA patients, which can improve the therapeutic effect by controlling disease activity factors, regulating bone metabolism indexes and Th17 cells, and has good safety. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
